This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeuroMetrix To Exhibit At American Diabetes Association 72nd Scientific Sessions

NeuroMetrix, Inc. (Nasdaq: NURO),, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported today that it will exhibit and participate in the American Diabetes Association (ADA) 72 nd Scientific Sessions. The ADA Scientific Sessions will be held on June 8-12 in Philadelphia at the Pennsylvania Convention Center.

NeuroMetrix will feature the NC-stat ® DPNCheck™, a medical device providing a fast, accurate, and quantitative point-of-care test for the detection of systemic neuropathies, such as diabetic peripheral neuropathy (DPN). DPN affects over 50% of people with diabetes and can trigger foot ulcers that may require amputation, as well as severe and debilitating foot and lower leg pain known as painful diabetic neuropathy. Over 500 NC-stat DPNCheck devices have been shipped since the fourth quarter of 2011. Live demonstrations of NC-stat DPNCheck will be conducted at the NeuroMetrix booth.

The clinical benefits of sural nerve conduction measurement at the point-of-care include:
  • Early detection of DPN, even in the absence of clinical symptoms and signs
  • Help with confirmation or rule-out of DPN and quantification of severity
  • Monitoring changes in DPN over time and in response to treatment

The company will also introduce the SENSUS™ pain management device. SENSUS is a transcutaneous electrical nerve stimulator uniquely designed to be used in managing chronic pain in the foot and lower leg, such as due to painful diabetic neuropathy. Several SENSUS devices will be on display at the NeuroMetrix booth to help physicians and other interested parties better understand how this novel device can benefit their diabetic patients suffering from painful diabetic neuropathy. SENSUS is the subject of a recent 510(k) premarket approval filing with the Food and Drug Administration (FDA) and is not currently available for commercial distribution.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.66 -0.09%
FB $118.57 0.84%
GOOG $698.30 0.76%
TSLA $241.82 0.44%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs